Right Ventricular Shape Distortion in Tricuspid Regurgitation

Ashley E Morgan¹, Atefeh Kashani¹, Brian Zenger¹, Lindsay C Rupp¹, Maura D Perez¹, Markus D Foote¹, Alan K Morris¹, Mark B Ratcliffe², Jiwon J Kim³, Jonathan W Weinsaft³, Vikas Sharma¹, Rob S MacLeod¹, Shireen Elhabian¹

¹ University of Utah, Salt Lake City, UT, USA
² University of California, San Francisco, and the San Francisco VA Medical Center
³ Weill-Cornell Medical College, NYC, NY, USA

Abstract

Tricuspid regurgitation (TR) is a failure in right-sided AV valve function which, if left untreated, leads to marked cardiac shape changes and heart failure. However, the specific right ventricular shape changes resulting from TR are unknown. The goal of this study is to characterize the RV shape changes of patients with severe TR. RVs were segmented from CINE MRI images. Using particle-based shape modeling (PSM), a dense set of homologous landmarks were placed with geometric consistency on the endocardial surface of each RV, via an entropy-based optimization of the information content of the shape model. Principal component analysis (PCA) identified the significant modes of shape variation across the population. These modes were used to create a patient-prediction model. 32 patients and 6 healthy controls were studied. The mean RV shape of TR patients demonstrated increased sphericity relative to controls, with the three most dominant modes of variation showing significant widening of the short axis of the heart, narrowing of the base at the RV outflow tract (RVOT), and blunting of the RV apex. By PCA, shape changes based on the first three modes of variation correctly identified patient vs. control hearts 86.5% of the time. The shape variation may further illuminate the mechanics of TR-induced RV failure and recovery, providing potential targets for therapies including novel devices and surgical interventions.

1. Introduction

Tricuspid regurgitation (TR) occurs when the leaflets of the tricuspid valve separating the right atrium and right ventricle (RV) do not seal completely, allowing back-flow of blood from the RV to the right atrium during systole. TR is caused by a diverse set of disorders—including congenital and acquired anomalies of the tricuspid valve, pulmonary vascular disease, and left heart failure. Once TR arises, it triggers an ongoing cycle of right-sided volume overload, RV dilation, and worsening TR. This cycle leads to progressive RV dysfunction and remodeling, and ultimately RV failure. Approximately 1.6 million Americans currently live with moderate or severe TR, a number increasing consistently over time [1, 2]. Severe TR is associated with significant risks, including an increased incidence of heart failure, 3–4-fold increased risk of major adverse cardiac events, and 2–3-fold risk of death [3–5]. Current research has shown that RV shape is correlated with function, and shape changes are associated with known markers of cardiovascular disease. For example, studies of pulmonary hypertension have shown increased RV eccentricity, while increased RV sphericity is associated with systemic hypertension, obesity, and smoking. Other studies have shown that shape changes correlate with symptom severity in patients with the congenital malformation of a dominant single ventricle [6–8]. However, the RV shape changes resulting from significant TR have not been previously described. Furthermore, these existing studies use crude approximations of shape, estimating changes based on a single parameter or empirical description of the morphological shape changes between healthy and diseased hearts. As such, no previous study has provided an objective, detailed characterization of RV shape changes in health vs patients with TR.

In this study, we evaluated the effect of TR on RV shape, and identified whether the major variants in RV shape could be used to identify RVs affected by TR. The study used cardiac magnetic resonance imaging (MRI) to construct three-dimensional RV models and assess shape changes using an open-source shape modeling tool, ShapeWorks [9], which has recently been shown to produce statistically consistent anatomical measurements and clinically relevant population-level shape modes of variations [10, 11]. We found statistical group differences between the RVs of patients with TR and controls with unprecedented detail. We also identified primary modes of shape variation and determined if these modes could correctly identify patients with TR based on shape differences alone.
2. Methods

2.1. Patient Cohort Selection

Patients with TR were identified using the University of Utah medical records database and a combination of procedure and diagnosis codes. Patient imaging data was analyzed from short axis CINE-MRI images, which were acquired as part of routine clinical care [12, 13]. All participants and use of clinical data were approved by the University of Utah Internal Review Board. Control MRIs were acquired from a previously collected healthy volunteer cohort at NYU-Langone Medical Center.

2.2. Model Generation and Shape Analysis

Short-axis CINE-MRI images were screened for quality and the RV endocardium was manually contoured at end-systole and end-diastole using the Seg3D open-source software package [14]. Contours were created using an implicit model tool to approximate the endocardial border of the right ventricle. The contours were exported as binary segmentations to ShapeWorks [9], where a particle-based shape modeling approach was applied. Specifically, segmentations were pre-processed [10] to place a dense set of homologous landmarks with geometric consistency on each RV endocardial surface. In particular, homologous landmarks (correspondence points) were automatically positioned on RV surfaces by optimizing the information content of the shape model via an entropy optimization scheme that balances the inherent trade-off between the statistical simplicity of the model (i.e., compactness or lowest entropy) and the accuracy of the geometric description of each shape (i.e., good surface samplings) [9]. We then computed statistical group differences [15] to characterize shape changes between the control and TR groups.

2.3. Statistical Shape Difference Analysis

Shape differences were compared between the control and patient groups by computing the mean location of each correspondence point for patient and control groups. These changes were verified using a bootstrap method to account for the varied differences in sample size between groups. Ten bootstrapped models with equal cohorts of six patients and six controls were created for this analysis.

2.4. Shape-based Prediction Model

We also constructed a shape-based prediction model to identify control vs. patient RV shapes. To build this model, we performed principal component analysis (PCA) on the correspondence points and mapped each RV shape to its respective PCA loading vector, which in turn encodes the dominant shape parameters that objectively characterize RV shapes. Our objective was to determine which shape parameters (i.e., PCA loadings) were most predictive of patient vs. control RV shapes. We determined the dimension $K$ of PCA loading vectors using the number of PCA components that explains 99% of the data variation. Here, we assume $s_i$ is the PCA loading vector of $K$—entries for shape $i$ and $y_i$ is the corresponding clinical label, where $y_i$ equal to 1 for patients and 0 for control subjects. We then solved a lasso regression [16] for $N = 1000$ random subsets of data, and estimated a weight vector, $w$ defined as

$$y_i = w^T s_i + \lambda |w|_1,$$

where $\lambda$ is a regularization parameter. A non-zero entry in $w$ shows the relevance of its respective PCA component to predicting patients. Then, we computed the dominance probability of each PCA component, defined as the number of times it appeared as a non-zero entry in $w$ divided by $N$. Subsequently, we selected the top three components with the highest probabilities to learn a logistic regression classifier for predicting patients, and to determine the accuracy of classification using these top three components.

3. Results

3.1. Patient Cohort

Between 2011 and 2019, 1,135 patients with a diagnosis of TR underwent cardiac MRI at the University of Utah. Of these, 41 had moderate or greater TR; 32 had acceptable image quality for analysis. Patient characteristics, including TR etiology and invasive hemodynamics, when available, are listed in Table 1. The TR patient group was on average 59 years old, had left ventricular ejection fraction (LVEF) of 47 ± 20%, and RVEF of 42 ± 15%. A right heart catheterization procedure had been performed in 13 of 32 TR patients. The average pulmonary artery (PA) systolic pressure was 45 ± 18 mmHg, and PA diastolic pressure was 21 ± 7 mmHg. In these patients, TR was caused by congenital heart disease (4), pulmonary hypertension (3), left-sided heart failure (8), atrial or ventricular arrhythmia (4), or dilated/restrictive cardiomyopathy (12).

3.2. Shape Differences

The mean shape difference between patient and control groups is shown in Figure 1. The average RV shape in patients with TR was more spherical and less triangular, with relative narrowing of the RV base, protrusion of the short axis of the mid-RV, and blunting of the RV apex. The maximum change between groups was an increase of 4 mm and a decrease of 6 mm in the overall RV shape. Bootstrapping experiments confirmed these results in magnitude, direction, and location of significant shape changes.
Table 1. Patient cohort baseline characteristics of interest

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mean (std)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/Female</td>
<td>9/33</td>
</tr>
<tr>
<td>Age</td>
<td>59(17.7)</td>
</tr>
<tr>
<td>LV Ejection Fraction (%)</td>
<td>47(20.2)</td>
</tr>
<tr>
<td>RV Ejection Fraction (%)</td>
<td>42(14.6)</td>
</tr>
<tr>
<td>Right Heart Cath</td>
<td>13/33</td>
</tr>
<tr>
<td>PA Systolic (mmHg)</td>
<td>44.5(20.9)</td>
</tr>
<tr>
<td>PA Diastolic (mmHg)</td>
<td>18.2(7.1)</td>
</tr>
<tr>
<td>Wedge Pressure (mmHg)</td>
<td>19.2(6.9)</td>
</tr>
</tbody>
</table>

Figure 1. RV shape changes in TR patients vs healthy controls.

### 3.3. Shape-based Prediction Model

We identified 18 modes of variation explaining 99% of the shape variability between patient and control groups (Figure 2). The three dominant modes of shape variation (modes 3, 5, and 9 in Figure 2) were selected to be used in the prediction model. Mode 3 showed blunting of the RV apex and protrusion of the RV free wall. Mode 5 highlighted relative narrowing of the RV base with widening of the short axis of the mid RV. Mode 9 primarily described widening of the mid RV. Using these three PCA modes, we correctly identified patient vs. control in 86.5% of cases.

Figure 2. Dominance probability of shape variation modes

4. Discussion

In this study, we objectively characterized specific details of RV shape distortion that occur with moderate to severe TR, and confirmed that the primary modes of shape variation can correctly identify these patients by shape alone. Specifically, we first determined the major differences in RV shape between healthy controls and patients with moderate to severe TR. We identified a significant increase in apical curvature (4 mm) and a significant decrease in inferior apical location (6 mm). Other studies have previously postulated an increase in RV shape ‘sphericity’ based on a minimal number of statistical and shape analyses. Our study isolated the specific regions of the RV that are distorted in patients with TR. Our results show that there are specific regions of significant change to RV shape that are indicative of TR.

We also showed that shape analysis can be used as a predictive tool. We found that, by isolating the three modes of highest variation from a PCA analysis, we could correctly identify patients vs. controls 86% of the time. This finding indicates that shape parameters associated with TR are well defined across a patient population and are identifiable from imaging data. Success in this predictive model suggests a possible shape-based TR diagnosis scheme, which could also be used as a risk stratification tool. Future development of this scheme will focus on the ability to identify shape changes associated with ‘minimal’ TR compared to severe TR that warrants clinical intervention.

This study has several limitations. First, TR is a dynamic process, which can depend on the volume status of the patient; because this study is retrospective and MRI was obtained at only one time point, it is impossible to know whether the patients had reversible TR and RV dysfunction which may have improved after resolution of a volume overloaded state, vs. fixed dysfunction due to end stage valvular and ventricular changes. Second, only 40% of the patients included in this study had invasive hemodynamic measurements, with available information regarding pulmonary and RV pressures. It is likely that this group of patients who underwent right heart catheterization were ‘sicker’, more likely to have significant pulmonary hypertension and RV dysfunction.

These methods have significant potential for future applications in the spectrum of RV disorders and RV failure. Despite the diversity of causes of TR represented in our patient population, RV shape changes followed several predictable patterns, as described above. These patterns were highly selective for identifying images of RVs with TR, relative to controls. Future studies will use the same methods to compare patients with similar etiologies of RV dysfunction but without TR, to the current patient population; we anticipate that such patients may have subtle RV shape changes that represent an earlier point on the spec-
trum of RV dysfunction, relative to the more advanced disease shown in the TR cohort. Furthermore, these images are ideally suited to future mechanics studies, such as the creation of finite element models, which will correlate the nuances of RV shape change with specific mechanical dysfunction to create a complete picture of RV disease.

Acknowledgments

This work was supported by the National Institutes of Health under grant numbers NIBIB-U24EB029011, NIAMS-R01AR076120, NHLBI-R01HL135568 (Elhabian), and NIGMS-P41GM103545 (MacLeod), NIH F30-HL149327 (Zenger), NIH R01-HL128278 (Weinsaft), NIH 5K-23-HL140092-03 (Kim). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References


Address for correspondence:
Ashley Morgan, MD
Division of Cardiothoracic Surgery
University of Utah
30 North 1900 E, SOM 36-127
Salt Lake City, Utah 84132
Ashley.Morgan@hsc.utah.edu